Epidemiological study of multiple sclerosis in Central America and the Caribbean (ENHANCE study) partial results of Costa Rica
DOI:
https://doi.org/10.51481/amc.v66i2.1407Keywords:
Multiple sclerosis, incidence, Central America and the Caribbean, diagnosis, clinical features, treatmentAbstract
Aim: This study aimed to describe the incidence and analyze the most relevant demographic, clinical, diagnostic, epidemiological and treatment characteristics; as well as the presence of known risk and prognostic factors, in Costa Rican patients with Multiple Sclerosis attended in three hospitals and included in the international initiative ENHANCE.
Methods: This observational study, a retrospective analysis of medical record information of MS patients aged 18 and older who received follow up in three hospitals of the Costa Rica´s national health care system, Caja Costarricense de Seguro Social (Hospital San Juan de Dios, Hospital San Rafael de Alajuela and Hospital San Carlos), between January 2014 and December 2019. All cases were used to determine the clinical and sociodemographic characteristics, only new cases were considered for incidence calculations and clinical and treatment outcomes were obtained from a patient subset that had active follow- up for at least 5 years.
Results: A total of 147 cases were identified, of which 72 were new cases during the study period, and 75 were incident or prevalent cases at 2014 with documented follow-up of at least 5 years. The average age at the onset of symptoms was 31.9 years, and 35.0 at the moment of diagnosis. A predominance of female cases was observed (69.4%, n=102), patients exhibited variable scores on the Expanded Disability Status Scale, ranging from 0 to 8.5 and the annual incidence in the analyzed population varied between 0.32 and 1.28 cases per 100.000 inhabitants. The main clinical form identified was relapsing-remitting (87.8%, n=129), with motor and sensory impairments being the primary affectations. Periventricular lesions (35%, n=45), were the most frequent documented in magnetic resonance imaging, and the majority of patients presented low levels of vitamin D. Regarding therapeutic management, there was a decrease in the use of traditional treatments (commonly referred to as first-line) and an increase in the use of new or second-line alternatives, such as ocrelizumab and natalizumab.
Conclusion: The data obtained in this study suggests that the analyzed population shows similar features to what has been reported in other internationally conducted studies and does not differ significantly from what has been previously described for the country.
Downloads
References
1. Filippi M, Bar-or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018;4:1–27. DOI: 10.1038/s41572-018-0041-4
2. Arteaga-Noriega A, Segura-Cardona AM, Castro-Álvarez JF, Zapata-Berrueco J, Vélez-Arroyave J, Rojas-Gualdrón DF. Factores asociados al tiempo libre de discapacidad en pacientes con Esclerosis Múltiple de un instituto de neurología en Medellín, Colombia. Rev Ecuatoriana Neurol. 2022;31:19–26. DOI: 10.46997/revecuatneurol31200019
3. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990 – 2016 : a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269–85. DOI: 10.1016/S1474-4422(18)30443-5
4. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26:27–40. DOI: 10.1111/ene.13819
5. Català-Senent JF, Andreu Z, Hidalgo MR, Soler-Sáez I, Roig FJ, Yanguas-Casás N, et al. A deep transcriptome meta-analysis reveals sex differences in multiple sclerosis. Neurobiol Dis. 2023;181:1–16. DOI: 10.1016/j.nbd.2023.106113
6. Bertado-Cortés B, Villamil-Osorio L, Carrera-Pineda R, Martínez-Cortés C, Guerrero-Cantera J. Características clínicas y demográficas de los pacientes con esclerosis múltiple. Rev Med Inst Mex Seguro Soc. 2016;54:86–90.
7. Alfredsson L, Olsson T. Lifestyle and Environmental Factors in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019; 8:1–12. DOI: 10.1101/cshperspect.a028944
8. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple sclerosis. 2020;26:1816–21. DOI:10.1177/1352458520970841
9. Ezabadi SG, Sahraian MA, Maroufi H, Shahrbaf MA, Eskandarieh S. Global assessment of characteristics of multiple sclerosis registries; A systematic review. Mult Scler Relat Disord. 2022;63:103928. DOI:10.1016/j.msard.2022.103928
10. Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. Bio Med Cent Neurol. 2013;13:1–13. DOI: 10.1186/1471-2377-13-128
11. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol. 2016;172:3–13. DOI:10.1016/j.neurol.2015.10.006.
12. Candeliere-Merlicco A, Valero-Delgado F, Martínez-Vidal S, Lastres-Arias C, Aparicio-Castro E, Toledo-Romero F, et al. Prevalence of multiple sclerosis in Health District III , Murcia , Spain. Mult Scler Relat Disord . 2016;9:31–5. DOI: 10.1016/j.msard.2016.06.003
13. Cristiano E, Rojas JI. Multiple sclerosis epidemiology in Latin America : An updated survey. Mult Scler Journal- Exp Transl Clin. 2017;1–7. DOI: 10.1177/2055217317715050
14. Gracia F, Armién B, Rivera V and Collaborative Multiple Sclerosis Group of Central America and Spanish Caribbean Region (CMSG), Rodríguez AVV, et al. Multiple Sclerosis in Central American and Spanish Caribbean Region: Should it be Recognized as a Public Health Problem? Journal of Epidemiology and Preventive Medicine. 2017;3:134.
15. Gracia F, Parajeles A, Panday A, Guirado-Romero AE, Molina Klee B, Treviño-Frenk I. Esclerosis múltiple en América Central y el Caribe: Estado actual y recomendaciones clínicas. Rev Mex Neurocienc. 2017;18:76–88.
16. Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J. 2017; 23:1123–1136. DOI:10.1177/1352458517694432
17.Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83:278-86. doi: 10.1212/WNL.0000000000000560.
18. Harbo HF, Gold R, Tintoré M. Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord. 2013; 6:237–248. DOI: 10.1177/1756285613488434
19. Perez-Carmona N, Gimenez-Martinez J, Borrego-Honrubia C, Sempere AP. Multiple sclerosis prevalence and doiincidence in San Vicente del Raspeig , Spain. Mult Scler Relat Disord. 2019; 33:78–81. DOI:10.1016/j.msard.2019.05.022
20. Correa-Diaz EP, Jácome-Sánchez E, Torres-Herrán G, Masabanda-Campaña L, Baño-Jiménez G, Altamirano-Brito MJ, et al. Factores Pronósticos de la Esclerosis Múltiple. Rev Ecuat Neurol. 2018; 27:62–71.
21. Garner Cruz O, Donaire Á, Ramírez Berlioz A, Wagner S, Rivera VM. Esclerosis múltiple: una revisión; el desafío en Honduras. Rev Med Hondur. 2015; 83:66–73.
22. Zhang G., Carillo-Vico A, Zhang W., Gao S., Izquierdo Ayuso G. Incidencia y prevalencia de la esclerosis múltiple en China y países asiáticos. Neurología. 2023; 38:159–72. DOI: 10.1016/j.nrl.2020.07.022
23.Moghaddam VK, Dickerson AS, Bazrafshan E, Seyedhasani SN, Najafi F, Hadei M, et al. Socioeconomic determinants of global distribution of multiple sclerosis: an ecological investigation based on Global Burden of Disease data. BMC Neurol. 2021; 21:1–11. DOI: 10.1186/s12883-021-02170-3
24. Lane J, Shin H, Poyser C, Lucas RM, Tremlett H. Multiple sclerosis incidence: A systematic review of change over time by geographical region. Mult Scler Relat Disord. 2022; 63:61–20. DOI: 10.1016/j.msard.2022.103932
25. Garcia-López F., García-Merino A, Alcalde-Cabero E, de Pedro-Cuesta J. Incidencia y prevalencia de la esclerosis múltiple en España. Una revisión sistemática. Neurología. 2022. DOI: 10.1016/j.nrleng.2022.02.004
26. Vásquez-Céspedes J, Fernández-Morales H, Valverde-Espinoza JA, Moraga-López A, Carazo-Céspedes K. Perfil demográfico y clínico de la esclerosis múltiple en Costa Rica: revisión de la casuística. Neurol Argentina. 2021; 13:69–77. DOI:10.1016/j.neuarg.2021.02.002
27. Fernández O, Fernández T, Arbizu T, Izquierdo G, Bosca I, Arroyo R, et al. Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain ( The Novo Study ). J Neurol. 2010; 257:1500–7. DOI: 10.1007/s00415-010-5560-1
28. Aires A, Barros A, Machado C, Fitas D, Cação G, Pedrosa R, et al. Atraso no Diagnóstico de Esclerose Múltipla numa População Portuguesa. Acta Med Port. 2019 ;32:289–94. DOI: 10.20344/amp.11187
29. Ghiasian M, Faryadras M, Mansour M, Khanlarzadeh E, Mazaheri S. Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990-2016. Acta Neurol Belg. 2021; 121:199–204. DOI: 10.1007/s12760-020-01528-7
30. Khedr EM, Malky I El, Hussein HB, Mahmoud DM, Gamea A. Multiple sclerosis diagnostic delay and its associated factors in Upper Egyptian patients. Sci Rep. 2023; 13:1–8. DOI: 10.1038/s41598-023-28864-x
31. Jamimovski D, Kavak K, Zakalik K, Coetzee T, Gottesman M, Coyle P, et al. Improvement in time to multiple sclerosis diagnosis:25-year retrospective analysis from New York State MS Consortium (NYSMSC). Mult J. 2023 ;29:753–6. DOI: 10.1177/13524585221140271
32. Rojas J, Carnero Contentti E, Henestroza P, Giachello S, Correale J. Time interval between disease onset and MS diagnosis during th last decade in Latin America. Mult Scler Relat Disord. 2021 ;48. DOI:10.1016/j.msard.2020.102672
33. Rojas JI, Patrucco L, Pappolla A, Cristiano E. Improvement over previous decades in time of diagnosis but not in time of initiating DMD in MS patients in Argentina. Mult Scler Relat Disord. 2021 ;52:1–3. DOI: 10.1016/j.msard.2021.103007
34. Breseghello Cavenaghi V, Martinho Dobrianskyj F, Sciascia do Olival G, Dias Carneiro R, Tilbery C. Characterization of the first symptoms of multiple sclerosis in a Brazilian center: cross-sectional study. Sao Paulo Med J. 2017; 135:222–5. DOI: 10.1590/1516-3180.2016.
35. Talavera Hernández C, Flores-Aldana M, Macías-Morales N, Flores Rivera J, Hernández Girón C. Vitamina D y Esclerosis Múltiple: Evidencia científica. Neurol Argentina. 2013; 5:250–8. DOI:10.1016/j.neuarg.2013.08.010
36. Pierrot-Deseilligny C, Souberbielle J. Vitamin D and multiple sclerosis: An update. Mult Scler Relat Disord. 2017; 14:35–45. DOI: 10.1016/j.msard.2017.03.014
37. Toro J, Reyes S, Díaz-Cruz C, Burbano L, Cuéllar-Giraldo DF, Duque A, et al. Vitamin D and other environmental risk factors in Colombian patients with multiple sclerosis. Mult Scler Relat Disord. 2020; 41:1–5. DOI:10.1016/j.msard.2020.101983
38. Chen-Ku CH, Jiménez-Navarrette M, Ulate Oviedo L. Hipovitaminosis D en Costa Rica, reporte inicial. Estudio de casos y controles. Acta Med Costarric. 2012; 54:146–151.
39. Gamboa T, Abarca G, Jiménez JG. Prevalence of 25-hydroxyvitamin D deficiency in healthy personnel from an academic institution of an urban area in Costa Rica. Research and Reports in Endocrine Disorders. 2015; 5: 135-140 DOI: 10.2147/RRED.S90435.
40. Fernández Liguori N, Seifer G, Villa AM, Garcea O. Fingolimod: un nuevo enfoque en el tratamiento de la esclerosis múltiple. Neurol Argentina. 2012; 4:144–151.
41. Gracia-García F, Treviño-Frenk I, Díaz-Jiménez A, Sirias-Baca A, Benzadón-Cohen A, Chinchilla-Weinstok D, et al. Experience with Fingolimod as an Evidence-based Therapy in Relapsing Remitting Multiple Sclerosis: A Central American Case Series. EC Neurol. 2019;11.7:465–474.
42. Correale J, Abad P, Alvarenga R, Alves-Leon S, Armas E, Barahona J, et al. Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization. J Neurol Sci. 2014; 339:196–206.DOI: 10.1016/j.jns.2014.02.017
43. Jasani KM, Sharaf N, Rog D, Aslam T. Fingolimod-associated macular oedema. BMJ Case Rep. 2017;1–2. DOI: 10.1136/bcr-2016-218912
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
